Want to see GB:OBD full AI Analyst Report?
OBD Stock Chart & Stats
0.12 p
>-0.01 p(-7.20%)
At close: 4:00 PM EDT
0.12 p
>-0.01 p(-7.20%)
Day’s Range― - ―
52-Week Range0.08 p - 0.50 p
Previous CloseN/A
Volume1.24M
Average Volume (3M)28.64M
Market Cap
£14.79M
Enterprise Value7.45T
Total Cash (Recent Filing)£2.51M
Total Debt (Recent Filing)£4.28M
Price to Earnings (P/E)―
Beta-0.38
Next Earnings
Jan 26, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding13,440,911,000
10 Day Avg. Volume39,084,974
30 Day Avg. Volume28,641,986
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)5.90
Price to Sales (P/S)6.02
P/FCF Ratio-0.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthRevenue growth of 22.21% indicates that Oxford BioDynamics is expanding commercial activity despite current losses. Continued top-line progress can support greater test adoption, partner engagement, and operating leverage if growth eventually outpaces the company’s cost base.
Proprietary PlatformThe 3D genome and epigenetic platform provides a specialized foundation for blood-based disease detection and patient-stratification tests. A proprietary technology base can support differentiated products, repeat applications across oncology, and licensing or partnership opportunities.
Multiple Revenue StreamsOxford BioDynamics has several routes to monetize its technology, including testing services, funded collaborations, milestone-style payments, and licensing. This model can broaden commercial opportunities and allow validated biomarkers to generate revenue across healthcare and research settings.
Bears Say
Persistent LossesPersistent negative net, gross, and EBIT margins show that revenue growth has not yet translated into a profitable operating model. Until pricing, volume, or cost efficiency improves, ongoing losses may constrain reinvestment and weaken the company’s ability to fund expansion internally.
High LeverageA debt-to-equity ratio of 4.58 indicates substantial reliance on debt relative to shareholder equity, while the low equity ratio suggests limited equity backing for assets. This reduces financial flexibility and can make future investment or recovery more dependent on external financing.
Weak Cash GenerationDeclining free cash flow growth and negative operating cash flow relative to net income indicate pressure on the company’s ability to convert operations into usable cash. Sustained cash weakness can limit funding for product development, commercialization, and debt obligations.
Oxford BioDynamics News
OBD FAQ
What was Oxford BioDynamics PLC’s price range in the past 12 months?
Oxford BioDynamics PLC lowest share price was 0.08 p and its highest was 0.50 p in the past 12 months.
What is Oxford BioDynamics PLC’s market cap?
Oxford BioDynamics PLC’s market cap is £14.79M.
When is Oxford BioDynamics PLC’s upcoming earnings report date?
Oxford BioDynamics PLC’s upcoming earnings report date is Jan 26, 2027 which is in 98 days.
How were Oxford BioDynamics PLC’s earnings last quarter?
Oxford BioDynamics PLC released its earnings results on Jun 30, 2026. The company reported -0.001 p earnings per share for the quarter.
Is Oxford BioDynamics PLC overvalued?
According to Wall Street analysts Oxford BioDynamics PLC’s price is currently Overvalued.
Does Oxford BioDynamics PLC pay dividends?
Oxford BioDynamics PLC does not currently pay dividends.
What is Oxford BioDynamics PLC’s EPS estimate?
Oxford BioDynamics PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oxford BioDynamics PLC have?
Oxford BioDynamics PLC has 13,440,911,000 shares outstanding.
What happened to Oxford BioDynamics PLC’s price movement after its last earnings report?
Oxford BioDynamics PLC reported an EPS of -0.001 p in its last earnings report. Following the earnings report the stock price went down -33.333%.
Which hedge fund is a major shareholder of Oxford BioDynamics PLC?
Currently, no hedge funds are holding shares in GB:OBD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Oxford BioDynamics PLC
Oxford BioDynamics Plc operates as a biotechnology firm that specializes in identifying and advancing biomarkers, primarily for the pharmaceutical and biotechnology sectors across global markets, including the United States. Its flagship offering is EpiSwitch, an exclusive technological platform employed for discovering, assessing, validating, and tracking epigenetic biomarkers, specifically referred to as chromosome conformation signatures. These are crucial for developing medical diagnostic kits, predicting disease onset, aiding in diagnosis, and informing therapeutic strategies. The company's key products encompass the EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a validated prognostic tool for forecasting patient responses to checkpoint inhibitor immunotherapy; the EpiSwitch CST (Covid Severity Test), a sophisticated blood test designed to predict the severity of COVID-19 in adults; and the EpiSwitch Explorer Array Kit, which enables high-resolution 3D genome analysis and novel biomarker discovery. Established in 2007, Oxford BioDynamics Plc maintains its headquarters in Oxford, United Kingdom.
Technical Analysis
IXICO plc
―
SkinBioTherapeutics
―
Fusion Antibodies Plc
―
Genflow Biosciences Plc
―
Aptamer Group Plc
―